Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Troublesome ticks: a new molecular toolkit to investigate zoonotic tick-borne pathogens in Australia. This project will use the latest molecular diagnostic techniques to address unanswered questions about potential tick-transmitted diseases of humans and companion animals in Australia. The study will identify 'hot-spots' for tick-borne pathogens, identify areas of potential risk for humans, and investigate vector-host-pathogen interactions nationwide.
Ecology and transmission of tick-borne disease in Australia. Ecology and transmission of tick-borne disease in Australia. This project aims to determine the bacterial, protozoal and viral biodiversity in wildlife ticks and their native mammal hosts, and provide new information about the biology and transmission dynamics of these microorganisms and their potential to cause disease in wildlife, domesticated animals and humans. Anticipated outcomes are improved diagnostic tests and management proto ....Ecology and transmission of tick-borne disease in Australia. Ecology and transmission of tick-borne disease in Australia. This project aims to determine the bacterial, protozoal and viral biodiversity in wildlife ticks and their native mammal hosts, and provide new information about the biology and transmission dynamics of these microorganisms and their potential to cause disease in wildlife, domesticated animals and humans. Anticipated outcomes are improved diagnostic tests and management protocols for tick-borne disease in Australia.Read moreRead less
Impact Of DTP Schedules On The Immunogenicity Of 2 Doses Of 13v-PCV Followed By An Early Booster
Funder
National Health and Medical Research Council
Funding Amount
$2,651,687.00
Summary
This project aims to come up with a vaccination schedule to make pneumococcal vaccines more effective and affordable for Fiji and other developing countries. We will evaluate schedules involving a 2 dose primary series in early infancy with a booster at 9 months of age. We will compare the immune responses to 3 different primary series and 2 booster options. The results of this project will be used to provide advice, at global and country levels, regarding introduction of pneumococcal vaccines.